Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of “Moderate Buy” from Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $13.80.

Several brokerages have weighed in on OBIO. Cowen started coverage on Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating on the stock. Barclays raised their target price on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. Finally, TD Cowen assumed coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They set a “buy” rating and a $15.00 target price for the company.

Institutional Investors Weigh In On Orchestra BioMed

Hedge funds have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at about $31,000. Creative Planning purchased a new stake in shares of Orchestra BioMed in the second quarter valued at approximately $40,000. XTX Topco Ltd purchased a new stake in shares of Orchestra BioMed in the second quarter valued at approximately $45,000. Jane Street Group LLC acquired a new position in shares of Orchestra BioMed during the 2nd quarter worth approximately $50,000. Finally, Bank of America Corp DE lifted its position in shares of Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after buying an additional 5,678 shares in the last quarter. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Price Performance

Shares of NASDAQ:OBIO opened at $4.80 on Friday. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.16. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32. The company has a market cap of $271.06 million, a PE ratio of -2.64 and a beta of 0.63. The company’s 50 day moving average is $4.42 and its 200 day moving average is $3.45.

Orchestra BioMed (NASDAQ:OBIO) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $0.74 million. On average, sell-side analysts forecast that Orchestra BioMed will post -1.66 EPS for the current year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.